News

In his new role, Mr Ros will lead the US sales and marketing strategy of Boehringer Ingelheim’s core brands. Mr Ros has been with Boehringer Ingelheim for 14

Prior to joining Stem Cell Therapeutics (SCT), Mr Herring was the president, CFO and director of Atlas Minerals. Prior thereto Mr Herring was the CFO of Velo Energy,

The board, after reviewing the proposal with its financial and legal advisors, has determined to reject the proposal. The company is actively pursuing a strategic alternative that the

From September 2001 to November 2008, Dr Llana held various positions of increasing responsibility at Biogen Idec, including most recently as the vice president of its oncology/rheumatology strategic

The financing round will support the commercialization of Singulex technologies in the diagnostics market. As part of the financing, Hironori Hozoji, investment officer for Jafco Life Science Investment,

“We made great progress during 2008 in a number of areas,” said chief executive officer Henri A. Termeer. “We delivered strong financial results, continued to grow our existing

Edward Richmond, formerly the executive vice president of operations, will assume the new position of executive vice president of customer solutions focusing on global customer service, program management,

The company has granted the underwriter of the offering a 45-day option to purchase up to an additional 457,500 units to cover over-allotments, if any. Net proceeds of

Niravam (alprazolam orally disintegrating tablets), Parcopa (carbidopa-levodopa orally disintegrating tablets) and Kemstro (baclofen orally disintegrating tablets) are central nervous system (CNS) products. Niravam and Parcopa have been commercially